|
시장보고서
상품코드
1941841
근접치료 시장 규모, 점유율과 동향 분석 : 투여 유형별, 용도별, 제품 유형별, 지역별, 부문 예측(2026-2033년)Brachytherapy Market Size, Share & Trends Analysis By Dosage Type (HDR, LDR), By Application (Prostate, Gynecological, Breast), By Product Seeds, Applicators & Afterloaders, Electronic Brachytherapy, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
근접치료 시장 요약
세계의 근접치료 시장 규모는 2025년에 11억 1,297만 달러로 추정되며, 2033년까지 19억 6,719만 달러에 이를 것으로 예측됩니다.
또한 2026-2033년 연평균 복합 성장률(CAGR) 7.4%를 나타낼 것으로 예측됩니다. 암 발병률 증가, 기술 발전, 방사선 치료의 도입이 크게 증가함에 따라 예측 기간 동안 시장 성장을 견인할 것으로 예측됩니다.
미국암협회(American Cancer Society)에 따르면, 2025년 미국 내 암으로 인한 사망자 수는 61만 8,000명, 신규 암 환자 수는 200만 명 이상으로 추산되며, 이러한 전 세계 암 부담 증가는 브라키테라피와 같은 효과적인 국소 치료법에 대한 수요를 지속적으로 증가시키고 있습니다. 지속적으로 증가하고 있습니다. 방사선 치료(브라키테라피 포함)는 예방적, 완화적 또는 근치적 치료에 사용되며, 단독요법 또는 수술, 면역요법, 화학요법의 보조요법으로 시행되기 때문에 의사들의 임상적 채택이 증가하고 있습니다. 2024년에는 영상 진단 및 치료 계획 시스템의 발전으로 방사선 치료의 선량 투여 정확도가 더욱 향상되고, 정상 조직에 대한 부수적 손상이 감소하여 임상 결과가 개선될 것으로 예측됩니다. 이를 통해 종합적인 암 치료에서 그 역할이 강화되었습니다.
2025년 현재 진행 중인 연구는 인공지능과 자동화된 치료 계획을 HDR(High Dose Rate) 방사선 치료 프로토콜에 통합하여 임상 워크플로우의 일관성과 효율성을 개선하고, 수동 계획의 편차를 해소하기 위해 진행 중입니다. 기술 발전에도 불구하고, 특히 중저소득 국가에서는 인프라 부족과 인력 부족으로 인해 도입에 걸림돌이 되고 있습니다. 국제원자력기구(IAEA)의 방사선 치료 센터 명단 등 세계 방사선 치료 자원 평가는 근접조사 장비의 불균등한 분포가 부각되고 있으며, 이는 이들 지역에서의 치료 격차의 큰 요인으로 작용하고 있습니다. 예를 들어, 2025년에는 미국 라듐 연구기구와 ASTRO가 ASTRO 연례총회에서 전용 소선원 치료 워크숍을 개최하여 레지던트 및 젊은 의사들의 실무 기술 강화를 위한 체계적인 강의와 실습 교육을 제공하여 시술 전문 지식의 부족을 해소하기 위해 노력했습니다.
보다 광범위하게는 2025년에 실시된 이니셔티브는 특히 의료 서비스가 부족한 지역에서 양질의 브라키테라피 서비스에 대한 접근성을 개선하기 위해 대상별 교육 프로그램 및 전문 역량 개발 행사를 통한 인재 양성 및 역량 강화에 중점을 두었습니다. 이러한 임상 훈련의 발전과 역량 강화 노력은 종합적으로 볼 때, 진화하는 시장 상황을 형성하고 표적 방사선 치료의 광범위한 보급을 뒷받침하는 중요한 요소로 작용하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 근접치료 시장 변수, 동향 및 범위
제4장 근접치료 시장 : 제품별 비즈니스 분석
제5장 근접치료 시장 : 투여 유형별 비즈니스 분석
제6장 근접치료 시장 : 용도별 비즈니스 분석
제7장 근접치료 시장 : 지역별 추정 및 동향 분석
제8장 경쟁 구도
LSHBrachytherapy Market Summary
The global brachytherapy market size was estimated at USD 1,112.97 million in 2025 and is projected to reach USD 1,967.19 million by 2033, growing at a CAGR of 7.4% from 2026 to 2033. The increasing prevalence of cancer, technological advancements, and a significant rise in the adoption of brachytherapy are expected to drive market growth during the forecast period.
According to the American Cancer Society, in the U.S., there were 618,000 cancer deaths and an estimated more than 2 million new cancer cases in 2025, and this rising global cancer burden continues to drive demand for effective localized treatment options such as brachytherapy. Radiation therapy, including brachytherapy, is used for prophylactic, palliative, or curative treatment and can be administered as monotherapy or as an adjunct to surgery, immunotherapy, and chemotherapy, increasing its clinical adoption among physicians. In 2024, advancements in imaging and treatment planning systems further enhanced the precision of brachytherapy dose delivery, reducing collateral damage to healthy tissues and improving clinical outcomes, which reinforced its role in comprehensive oncological care.
Ongoing research in 2025 is integrating artificial intelligence and automated treatment planning into high-dose-rate (HDR) brachytherapy protocols to improve consistency and efficiency of clinical workflows, addressing variability in manual planning practices. Despite technological progress, access challenges persist, particularly in low- and middle-income countries, where limited infrastructure and workforce shortages continue to restrict uptake; global radiotherapy resource assessments, such as the IAEA's Directory of Radiotherapy Centres, highlight the uneven distribution of brachytherapy units, which contributes to significant treatment gaps in these regions. For instance, in 2025, the American Radium Research Organization and ASTRO conducted a dedicated Brachytherapy Workshop during the ASTRO Annual Meeting, offering structured didactic sessions alongside hands-on training to strengthen practical brachytherapy competencies among residents and early-career physicians, thereby addressing gaps in procedural expertise.
More broadly, initiatives undertaken in 2025 emphasized workforce training and capacity building through targeted educational programs and professional development events aimed at improving access to high-quality brachytherapy services, particularly in underserved regions. Collectively, these clinical training advancements and capacity-building efforts are key factors shaping the evolving market landscape and supporting wider adoption of this targeted radiation therapy modality.
Global Brachytherapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global brachytherapy market report based on product, dosage type, application, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Seeds
- Applicators & Afterloaders
- Electronic Brachytherapy
- Dosage type Outlook (Revenue, USD Million, 2021 - 2033)
- High-Dose Rate (HDR)
- Low-Dose Rate (LDR)
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Prostate
- Gynecological Cancer
- Breast
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Dosage type
- 1.2.3. Application
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Brachytherapy Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Brachytherapy Market: Product Business Analysis
- 4.1. Product Market Share, 2025 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Seeds
- 4.4.1. Seeds Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Applicators & Afterloaders
- 4.5.1. Applicators & Afterloaders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Electronic Brachytherapy
- 4.6.1. Electronic Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Brachytherapy Market: Dosage Type Business Analysis
- 5.1. Dosage type Market Share, 2025 & 2033
- 5.2. Dosage type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Dosage type, 2021 to 2033 (USD Million)
- 5.4. High-Dose Rate (HDR)
- 5.4.1. High-Dose Rate (HDR) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Low-Dose Rate (LDR)
- 5.5.1. Low-Dose Rate (LDR) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Brachytherapy Market: Application Business Analysis
- 6.1. Application Market Share, 2025 & 2033
- 6.2. Application Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Prostate
- 6.4.1. Prostate Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Gynecological Cancer
- 6.5.1. Gynecological Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Breast
- 6.6.1. Breast Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Brachytherapy Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2025 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Brachytherapy Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Type Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Type Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. Canada Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Type Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Type Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. UK Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Type Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Type Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Type Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Type Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Type Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Type Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Type Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Type Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Type Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Type Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Type Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Type Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Type Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Type Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Brazil Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Type Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. Argentina Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Type Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Type Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Type Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Type Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Brachytherapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Elekta AB
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Varian Medical Systems
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Eckert & Ziegler BEBIG
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. IsoRay
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Theragenics Corporation
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. Best Medical International
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. CIVCO Medical Solutions
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Argon Medical Devices
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Panacea Medical Technologies
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Becton, Dickinson and Company
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
- 8.5.1. Elekta AB
